📰 Gravis Foundation News
Page 2 - Gravis Foundation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gravis Foundation. Real-time updates on events, politics, business and more.
September 26, 2023
UCB announces approval of RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in JapanJapanese Ministry of Health, Labour and Welfare (MHLW) approves two UCB treatments, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan), f...
September 25, 2023
UCB announces approval of RYSTIGGO[®] and ZILBRYSQ[®] for the treatment of adult patients with generalized myasthenia gravis in Japan Japanese Ministry...
July 21, 2023
RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody...
June 30, 2023
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology Meeting Results presented across...
June 27, 2023
UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under...
June 27, 2023
The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.
June 1, 2023
/PRNewswire/ -- The MG Community around the world is turning Awareness into Action in June to educate everyone about the challenges of the rare neuromuscular...
February 27, 2023
/PRNewswire/ -- Two patient-centric advocacy organizations have created an alliance to help patients with chronic disease navigate the health care system....
January 25, 2023
/PRNewswire/ -- The Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization solely dedicated to the myasthenia...
January 6, 2023
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...